TScan Therapeutics Files Definitive Proxy Statement

TL;DR

TSCN proxy statement filed. Shareholders vote on company matters.

AI Summary

TScan Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on May 14, 2025, for its fiscal year ending December 31, 2024. The filing pertains to the company's annual meeting and related corporate governance matters. The company is based in Waltham, MA, and operates in the biological products sector.

Why It Matters

This filing provides shareholders with crucial information regarding the company's governance, executive compensation, and voting matters ahead of their annual meeting, enabling informed participation.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) that does not contain new financial results or significant operational changes.

Key Players & Entities

• TScan Therapeutics, Inc. (company) — Registrant
• 0001783328 (company) — Central Index Key
• Waltham, MA (location) — Company Headquarters
• May 14, 2025 (date) — Filing Date
• December 31, 2024 (date) — Fiscal Year End

FAQ

From the Filing

0001193125-25-119378.txt : 20250514 0001193125-25-119378.hdr.sgml : 20250514 20250514070111 ACCESSION NUMBER: 0001193125-25-119378 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250514 DATE AS OF CHANGE: 20250514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 25942591 BUSINESS ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 DEF 14A 1 d892399ddef14a.htm DEF 14A DEF 14A Table of Contents DEF 14A false 0001783328 0001783328 2024-01-01 2024-12-31     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:   ☐ Preliminary Proxy Statement   ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))   ☒ Definitive Proxy Statement   ☐ Definitive Additional Materials   ☐ Soliciting Material Pursuant to §240.14a-12 TSCAN THERAPEUTICS, INC. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):   ☒ No fee required.   ☐ Fee paid previously with preliminary materials.   ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.       Table of Contents TSCAN THERAPEUTICS, INC. 830 Winter Street Waltham, MA 02451 NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS To be held June 30, 2025 Notice is hereby given that the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of TScan Therapeutics, Inc. (the “Company” or “we”), will be held online on June 30, 2025, at 8:30 a.m. Eastern Time. You may attend the meeting virtually via the Internet at www.virtualshareholdermeeting.com/TCRX2025, where you will be able to vote electronically and submit questions. You will need the 16-digit control number included with the Notice of Internet Availability of Proxy Materials being mailed to you separately in order to attend the Annual Meeting. The purpose of the Annual Meeting is the following:   1. To elect three Class I directors to the Company’s board of directors, each to serve until the 2028 annual meeting of stockholders and until such director’s successor has been duly elected and qualified, or until such director’s earlier death, resignation or removal;   2. To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025; and   3. To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting. The proposal for the election of directors relates solely to the election of Class I directors nominated by the board of directors. Only the Company’s stockholders of record at the close of business on May 7, 2025, the record date for the Annual Meeting, are entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement of the Annual Meeting. You can find more information on each of the matters to be voted on at the Annual Meeting, including information r